Clinico-pathologic factors associated with the occurrence of early and late metastatic spread in a cohort of breast cancer patients.
暂无分享,去创建一个
S. González | N. Giménez | C. Chabrera | E. Vallejo | M. Garcia-Font | C. Gónzalez | P. Zarco | M. Fraile | I. Larrañaga | I. Barco | Antonio García-Fernández | M. García-Font
[1] J. Sparano,et al. The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes , 2021, Therapeutic advances in medical oncology.
[2] S. González,et al. Factors associated with the development of distant metastases in breast cancer patients—A regression model predicting organ relapse , 2020, The breast journal.
[3] K. Friedrichs,et al. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study , 2019, Breast Cancer Research and Treatment.
[4] S. Narod,et al. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer , 2018, Breast Cancer Research and Treatment.
[5] S. Tyldesley,et al. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed , 2017, Breast Cancer Research and Treatment.
[6] M. de Boer,et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? , 2015, British Journal of Cancer.
[7] Keda Yu,et al. Difference between observed and expected number of involved lymph nodes reflects the metastatic potential of breast cancer independent to intrinsic subtype , 2015, Oncotarget.
[8] S. González,et al. Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification , 2015, Clinical and Translational Oncology.
[9] X. Pivot,et al. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. , 2014, Breast.
[10] Mark J. Ratain,et al. Tumour heterogeneity in the clinic , 2013, Nature.
[11] Nuria Giménez,et al. Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: analytical survey from 1997 to 2012 , 2013, Tumor Biology.
[12] L. Fallowfield,et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] L. Collins,et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer , 2012, Breast Cancer Research and Treatment.
[14] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Massagué,et al. Molecular basis of metastasis. , 2008, The New England journal of medicine.
[16] M. Namer,et al. Prognostic factors in 1,038 women with metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] J. Coebergh,et al. An overview of prognostic factors for long-term survivors of breast cancer , 2007, Breast Cancer Research and Treatment.
[18] J. Boyages,et al. TUMOUR SIZE AS A PREDICTOR OF AXILLARY NODE METASTASES IN PATIENTS WITH BREAST CANCER , 2006, ANZ journal of surgery.
[19] Wei Wei,et al. Metastatic patterns in adenocarcinoma , 2006, Cancer.
[20] Jenny C. Chang,et al. Survival of patients with metastatic breast carcinoma , 2003, Cancer.
[21] Kevin Hughes,et al. Predicting the survival of patients with breast carcinoma using tumor size , 2002, Cancer.